Screener
Novavax NVAX Proceeds from sale of assets
Proceeds from sale of assets at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.
The source filing: Novavax’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:33 AM EST
- Fiscal year
- FY2025
- Accession
- 0001000694-26-000007
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Capital expenditures | (5,560) | (13,057) | (53,771) |
| Internal-use software | (828) | (1,582) | (5,035) |
| Proceeds from Assets held for sale | 19,653 | — | — |
| Proceeds from disposition of Novavax CZ assets | — | 192,643 | — |
| Purchases of marketable securities | (445,267) | (825,593) | — |
| Proceeds from maturities of marketable securities | 353,735 | 443,551 | — |
| Net cash used in investing activities | (78,267) | (204,038) | (58,806) |
| Financing Activities: |
Item 16. FORM 10-K SUMMARY
FAQ
- What is Novavax's proceeds from sale of assets?
- Novavax (NVAX) reported proceeds from sale of assets of $0 in Q4 2025.
- How has Novavax's proceeds from sale of assets changed year-over-year?
- Novavax's proceeds from sale of assets decreased by 100.0% year-over-year, from $48.16M to $0.
- What does proceeds from sale of assets mean?
- Proceeds from sale of assets
Ask your AI about Novavax's proceeds from sale of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude